Oak Park, IL – According to filings with the U.S. Securities and Exchange Commission, Adze Biotechnology is raising $3,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Sidney Hopps played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Adze Biotechnology

Adze Biotechnology is developing oncolytic immunotherapies with multiple mechanisms of action that can be combined with PD-(L)1 backbones. Our goal is to treat tumors directly while recruiting and amplifying the patient’s immune response to fight cancers. Adze Biotechnology is a pre-clinical stage company developing systemically deliverable oncolytic immunotherapies for the treatment of cancers with significant unmet needs. Adze Biotechnology has exclusive licenses to oncolytic immunotherapies developed in the lab of Dr Michael Barry of Mayo Clinic.

To learn more about Adze Biotechnology, visit http://adzebiotech.com/

Contact:
Sidney Hopps, Chief Executive Officer
917-743-9401
https://www.linkedin.com/in/sidney-hopps-9090662/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved